Dharti Proteins trading window shut Oct 2026 for results

Trading window closure: what the company disclosed

Dharti Proteins Limited said it has closed its trading window for dealing in the company’s equity shares starting October 1, 2026. The restriction will remain in force until 48 hours after the company declares its unaudited financial results for the quarter and half-year ended September 30, 2026. Trading window closures are typically used to limit dealing by insiders and connected persons during sensitive periods. The announcement ties the window reopening directly to the timing of the results disclosure. The company did not provide a specific date for the results announcement in the information shared. But the trigger for reopening is clearly defined as a 48-hour period after the results are declared. For investors tracking compliance updates, the key point is that October 1, 2026 marks the start of the restricted period.

How long the restriction lasts and the key condition

The closure is not described as a fixed number of days. Instead, it is event-based and ends only after a disclosure milestone is reached. The company linked the end of the restriction to the declaration of unaudited financial results for the quarter and half-year ended September 30, 2026. The window will open 48 hours after those results are declared. This is a standard compliance approach in many listed entities, where trading is restricted around financial reporting windows. The content provided does not detail who the restriction applies to, such as designated persons, insiders, or connected persons. It also does not list any exemptions or pre-clearance rules. So, the only firm details available are the start date, the results period, and the 48-hour post-results condition.

AGM agenda flags major financing and limit enhancements

Alongside the compliance update, the AGM agenda includes multiple financial resolutions described as critical. The agenda includes a proposal to approve an unsecured loan of up to ₹100 crore from Managing Director Jatinbhai Ramanbhai Patel. It also includes a proposal to enhance the company’s borrowing limits under Section 180(1)(c) of the Companies Act, 2013 to a maximum of ₹5,000 crore. Separately, it proposes to enhance limits for loans, guarantees, and investments under Section 186 of the Companies Act, 2013 to an aggregate amount not exceeding ₹5,000 crore. These items, taken together, point to a focus on expanding financial flexibility. The agenda details, as provided, do not specify the timing of drawdowns or the intended use of funds. They also do not specify whether the higher limits will be used immediately or kept available as headroom.

₹100 crore convertible loan from the Managing Director

The proposed unsecured loan of up to ₹100 crore from Managing Director Jatinbhai Ramanbhai Patel includes an option to convert outstanding principal and/or interest into equity shares at a later date. The conversion is stated to be subject to SEBI guidelines. The information shared describes this as a “strategic shift in capital sourcing.” It also frames the arrangement as related-party financing that could provide liquidity without immediate dilution. Since the loan includes a conversion option, any eventual equity issuance would depend on the future conversion terms and compliance requirements. However, the provided material does not specify a conversion price, conversion ratio, maturity, coupon, or any conversion timeline. It only states that conversion is an option and subject to SEBI guidelines.

Why the capital context is central to the proposal

The rationale section included with the agenda notes that, as of March 31, 2026, the company’s paid-up share capital was ₹50 lakh and it had no free reserves or securities premium. Based on the same note, the convertible loan is positioned as a way to raise liquidity without immediately issuing new shares. This matters because a company with limited reserves may have fewer internal resources to fund working capital or new initiatives. That said, the broader company data included elsewhere in the provided text lists paid-up capital as ₹10.3 crore. The input does not reconcile this difference, so readers should treat the figures as coming from different parts of the provided material. The AGM resolutions and explanatory note are the only places that explain the intent and reasoning behind the proposed MD funding.

Borrowing and investment limit enhancements: what changes

Two separate limit enhancements appear on the AGM agenda. Under Section 180(1)(c) of the Companies Act, 2013, the company proposes increasing its maximum borrowing limit to ₹5,000 crore. Under Section 186 of the Companies Act, 2013, it proposes increasing the aggregate ceiling for loans, guarantees, and investments to ₹5,000 crore. These resolutions generally provide enabling authority rather than immediate borrowings or investments. The provided text does not indicate existing borrowing levels, bank lines, or debt outstanding. It also states that Dharti Proteins Limited does not have any charges (loans) registered with the Registrar of Companies. If accurate as stated, the lack of registered charges suggests there may not be secured borrowings recorded in that particular registry view. But the material does not provide a complete debt schedule, so the statement should be read in that limited context.

Listing identifiers and trading status noted in the material

The company is identified with BSE code 531171 and NSE symbol DHARTI. The ISIN listed is INE248C01013. The note also labels the group as XT and marks the stock as “Suspended.” The input also states the current status of Dharti Proteins Limited is “Active,” which can refer to the company’s corporate status rather than exchange trading status. The provided text does not explain the reason for the suspension or how long it has been in effect. It also does not provide recent price data beyond a single datapoint: the share price is stated as ₹3.45 as on 31/08/2025. No further market data, volumes, or recent price movement is included.

Business profile and locations mentioned

Dharti Proteins Ltd. (formerly known as Devika Proteins Ltd.) is described as being engaged in manufacturing edible and non edible oil, oil cakes and de-oil cakes. The registered address is stated as 203-ABHIJEET 1 MITHAKHALI SIX ROAD, Ellisbridge, Ahmadabad City, Ahmedabad, Gujarat - 380006. The CIN provided is L67120GJ1994PLC022199. A company URL is listed as https://www.devikaproteins.com. Another address is also mentioned as the headquarters location: Shop No. 212, 2nd Floor, Ganesh Glory 11, Nr BSNL, Nr. Ganesh Genisis, S.G. Highway Jagatpur, Ahmedabad, Gujarat, 382470, India. The input does not clarify whether both addresses are currently used for different purposes, such as registered office and corporate office.

Key facts table

What investors will watch next

The next formal milestone referenced is the declaration of unaudited financial results for the quarter and half-year ended September 30, 2026. That disclosure will determine when the trading window restriction ends, with a 48-hour cooling-off period after the results announcement. Separately, the AGM resolutions, if approved, would expand the company’s financial headroom materially through higher statutory limits and an MD-backed convertible loan proposal. The details provided do not include the AGM date, voting outcomes, or any filing references. They also do not specify the commercial terms of the convertible loan beyond the conversion option and SEBI-guideline condition. For shareholders and observers, the key is to track the eventual results announcement and any subsequent disclosures on the AGM decisions and financing structure.

Conclusion

Dharti Proteins Limited has shut its trading window from October 1, 2026, with reopening tied to the declaration of unaudited results for the quarter and half-year ended September 30, 2026 plus 48 hours. The AGM agenda, meanwhile, highlights a ₹100 crore unsecured convertible loan proposal from the Managing Director and proposals to raise borrowing and investment-related limits to ₹5,000 crore each. The next confirmed step in the timeline is the results declaration, which will also set the schedule for the trading window to reopen under the stated rule.